CAR-T therapies have transformed hematologic cancer care, achieving high remission but facing relapse, toxicity, cost, and slow manufacturing. Innovations include mRNA-based in vivo CAR-T generation for...
Researchers developed CAR-STAb, a new immunotherapy combining CAR-T cells and bispecific antibodies, showing promise against B-cell malignancies in animal models. It recruits additional immune cells, blocking...
Roche is acquiring Poseida Therapeutics for up to $1.5 billion, emphasizing its strategic focus on innovative allogeneic CAR-T cancer therapies. Poseida’s candidate P-BCMA-ALLO1 shows promise in...